Lineage Intangible Assets vs Deferred Long Term Liab Analysis

LCTX Stock

USD 0.49 0.01 2.00%

Lineage Cell financial indicator trend analysis is infinitely more than just investigating Lineage Cell Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lineage Cell Therapeutics is a good investment. Please check the relationship between Lineage Cell Intangible Assets and its Deferred Long Term Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Intangible Assets vs Deferred Long Term Liab

Intangible Assets vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lineage Cell Therapeutics Intangible Assets account and Deferred Long Term Liab. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Lineage Cell's Intangible Assets and Deferred Long Term Liab is 0.48. Overlapping area represents the amount of variation of Intangible Assets that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Lineage Cell Therapeutics, assuming nothing else is changed. The correlation between historical values of Lineage Cell's Intangible Assets and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Intangible Assets of Lineage Cell Therapeutics are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Intangible Assets i.e., Lineage Cell's Intangible Assets and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

0.48

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from Lineage Cell's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lineage Cell Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Lineage Cell reported Tax Provision of (1.8 Million) in 2024. Issuance Of Capital Stock is likely to rise to about 37.7 M in 2025, whereas Selling General Administrative is likely to drop slightly above 11.3 M in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	36.5M	33.0M	30.6M	21.4M
Cost Of Revenue	728K	671K	334K	570.7K

Total Operating Expenses Cost Of Revenue

Lineage Cell fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Other Current Assets	Property Plant And Equipment Gross	Inventory	Other Current Liab	Common Stock Total Equity	Common Stock	Short Long Term Debt Total	Current Deferred Revenue	Short Term Debt
Total Assets		0.6	0.88	-0.57	-0.7	0.06	0.61	0.75	0.71	0.5	0.36	0.57	0.77	0.7	0.86	0.42	0.0	-0.26	0.71	-0.64	0.55	0.81	0.82	0.51	0.48	-0.45
Total Current Liabilities	0.6		0.23	-0.61	-0.6	-0.09	0.62	0.69	0.55	0.85	0.81	0.96	0.87	0.26	0.19	0.03	-0.14	0.02	0.68	-0.36	0.92	0.55	0.56	0.28	0.93	-0.16
Total Stockholder Equity	0.88	0.23		-0.34	-0.52	0.07	0.39	0.52	0.6	0.17	0.13	0.21	0.51	0.62	0.9	0.3	0.12	-0.31	0.48	-0.62	0.23	0.68	0.69	0.42	0.14	-0.31
Net Debt	-0.57	-0.61	-0.34		0.57	0.21	-0.99	-0.7	-0.54	-0.45	-0.48	-0.55	-0.65	-0.19	-0.31	-0.24	0.06	0.19	-0.47	0.35	-0.55	-0.58	-0.57	-0.13	-0.58	0.15
Retained Earnings	-0.7	-0.6	-0.52	0.57		0.14	-0.63	-0.85	-0.97	-0.76	-0.14	-0.71	-0.71	-0.55	-0.46	-0.11	-0.01	0.1	-0.93	0.62	-0.32	-0.97	-0.97	-0.53	-0.67	0.14
Accounts Payable	0.06	-0.09	0.07	0.21	0.14		-0.2	-0.21	-0.17	-0.27	0.0	-0.19	-0.07	0.21	0.14	0.35	0.43	-0.06	-0.17	0.14	0.07	-0.12	-0.11	-0.01	-0.31	-0.38
Cash	0.61	0.62	0.39	-0.99	-0.63	-0.2		0.75	0.61	0.48	0.45	0.57	0.69	0.26	0.35	0.27	-0.07	-0.19	0.54	-0.42	0.54	0.65	0.64	0.23	0.6	-0.17
Cash And Short Term Investments	0.75	0.69	0.52	-0.7	-0.85	-0.21	0.75		0.83	0.74	0.37	0.75	0.87	0.53	0.41	0.23	-0.06	-0.18	0.83	-0.59	0.52	0.84	0.84	0.54	0.69	-0.27
Common Stock Shares Outstanding	0.71	0.55	0.6	-0.54	-0.97	-0.17	0.61	0.83		0.73	0.17	0.67	0.71	0.48	0.49	0.05	0.01	-0.1	0.88	-0.68	0.28	0.98	0.98	0.5	0.63	-0.05
Non Current Liabilities Total	0.5	0.85	0.17	-0.45	-0.76	-0.27	0.48	0.74	0.73		0.5	0.97	0.76	0.17	0.12	-0.15	-0.23	-0.05	0.81	-0.34	0.61	0.69	0.69	0.3	0.93	-0.02
Other Stockholder Equity	0.36	0.81	0.13	-0.48	-0.14	0.0	0.45	0.37	0.17	0.5		0.67	0.7	-0.02	-0.03	-0.04	-0.08	0.17	0.22	-0.19	0.91	0.13	0.14	-0.01	0.67	0.01
Total Liab	0.57	0.96	0.21	-0.55	-0.71	-0.19	0.57	0.75	0.67	0.97	0.67		0.84	0.22	0.16	-0.07	-0.19	-0.02	0.77	-0.37	0.79	0.65	0.65	0.3	0.97	-0.09
Total Current Assets	0.77	0.87	0.51	-0.65	-0.71	-0.07	0.69	0.87	0.71	0.76	0.7	0.84		0.52	0.34	0.18	-0.07	0.01	0.75	-0.52	0.8	0.71	0.72	0.5	0.77	-0.27
Property Plant And Equipment Net	0.7	0.26	0.62	-0.19	-0.55	0.21	0.26	0.53	0.48	0.17	-0.02	0.22	0.52		0.61	0.55	0.18	0.13	0.62	-0.6	0.23	0.58	0.6	0.78	0.11	-0.51
Non Current Assets Total	0.86	0.19	0.9	-0.31	-0.46	0.14	0.35	0.41	0.49	0.12	-0.03	0.16	0.34	0.61		0.48	0.05	-0.4	0.45	-0.52	0.18	0.62	0.63	0.36	0.09	-0.45
Non Currrent Assets Other	0.42	0.03	0.3	-0.24	-0.11	0.35	0.27	0.23	0.05	-0.15	-0.04	-0.07	0.18	0.55	0.48		-0.11	0.12	0.15	-0.37	0.11	0.15	0.16	0.3	-0.13	-0.38
Other Assets	0.0	-0.14	0.12	0.06	-0.01	0.43	-0.07	-0.06	0.01	-0.23	-0.08	-0.19	-0.07	0.18	0.05	-0.11		-0.11	-0.06	-0.12	-0.06	0.02	0.03	-0.07	-0.22	-0.29
Other Current Assets	-0.26	0.02	-0.31	0.19	0.1	-0.06	-0.19	-0.18	-0.1	-0.05	0.17	-0.02	0.01	0.13	-0.4	0.12	-0.11		-0.04	-0.27	0.02	-0.2	-0.2	0.18	0.0	0.43
Property Plant And Equipment Gross	0.71	0.68	0.48	-0.47	-0.93	-0.17	0.54	0.83	0.88	0.81	0.22	0.77	0.75	0.62	0.45	0.15	-0.06	-0.04		-0.66	0.42	0.89	0.9	0.66	0.75	-0.13
Inventory	-0.64	-0.36	-0.62	0.35	0.62	0.14	-0.42	-0.59	-0.68	-0.34	-0.19	-0.37	-0.52	-0.6	-0.52	-0.37	-0.12	-0.27	-0.66		-0.24	-0.65	-0.66	-0.62	-0.37	-0.09
Other Current Liab	0.55	0.92	0.23	-0.55	-0.32	0.07	0.54	0.52	0.28	0.61	0.91	0.79	0.8	0.23	0.18	0.11	-0.06	0.02	0.42	-0.24		0.31	0.32	0.17	0.74	-0.27
Common Stock Total Equity	0.81	0.55	0.68	-0.58	-0.97	-0.12	0.65	0.84	0.98	0.69	0.13	0.65	0.71	0.58	0.62	0.15	0.02	-0.2	0.89	-0.65	0.31		1.0	0.53	0.58	-0.22
Common Stock	0.82	0.56	0.69	-0.57	-0.97	-0.11	0.64	0.84	0.98	0.69	0.14	0.65	0.72	0.6	0.63	0.16	0.03	-0.2	0.9	-0.66	0.32	1.0		0.54	0.59	-0.23
Short Long Term Debt Total	0.51	0.28	0.42	-0.13	-0.53	-0.01	0.23	0.54	0.5	0.3	-0.01	0.3	0.5	0.78	0.36	0.3	-0.07	0.18	0.66	-0.62	0.17	0.53	0.54		0.25	-0.18
Current Deferred Revenue	0.48	0.93	0.14	-0.58	-0.67	-0.31	0.6	0.69	0.63	0.93	0.67	0.97	0.77	0.11	0.09	-0.13	-0.22	0.0	0.75	-0.37	0.74	0.58	0.59	0.25		0.09
Short Term Debt	-0.45	-0.16	-0.31	0.15	0.14	-0.38	-0.17	-0.27	-0.05	-0.02	0.01	-0.09	-0.27	-0.51	-0.45	-0.38	-0.29	0.43	-0.13	-0.09	-0.27	-0.22	-0.23	-0.18	0.09

Click cells to compare fundamentals

Lineage Cell Account Relationship Matchups

Lineage Cell fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	107.9M	174.5M	123.7M	101.0M	113.2M	118.9M
Total Current Liabilities	7.8M	47.1M	19.0M	18.0M	14.0M	14.7M
Total Stockholder Equity	96.2M	92.2M	73.3M	63.4M	77.0M	80.9M
Net Debt	(29.3M)	(52.9M)	(7.5M)	(32.5M)	(43.3M)	(41.1M)
Retained Earnings	(294.1M)	(337.1M)	(363.4M)	(384.9M)	(403.5M)	(383.3M)
Accounts Payable	2.6M	3.5M	2.4M	2.0M	1.2M	2.1M
Cash	32.6M	55.7M	11.4M	35.4M	45.8M	48.1M
Cash And Short Term Investments	41.6M	58.4M	57.9M	35.5M	47.8M	50.2M
Common Stock Shares Outstanding	150.0M	164.5M	169.8M	172.7M	200.2M	210.2M
Liabilities And Stockholders Equity	107.9M	174.5M	123.7M	101.0M	113.2M	118.9M
Non Current Liabilities Total	5.1M	36.5M	32.7M	21.0M	22.2M	23.3M
Other Stockholder Equity	(3.7M)	433.2M	(3.6M)	(1.4M)	(1.4M)	(1.3M)
Total Liab	12.8M	83.6M	51.7M	39.0M	36.2M	38.0M
Total Current Assets	44.0M	111.5M	60M	38.4M	51.0M	53.5M
Property Plant And Equipment Net	5.6M	4.9M	5.7M	4.8M	4.4M	2.3M
Non Current Assets Total	64.0M	63.0M	63.7M	62.6M	62.2M	65.3M
Non Currrent Assets Other	616K	630K	627K	577K	614K	561.1K
Other Assets	864K	616K	630K	627K	564.3K	536.1K
Other Current Assets	2.4M	2.4M	1.8M	2.2M	2.6M	1.4M
Property Plant And Equipment Gross	5.6M	10.2M	11.5M	12.0M	8.8M	9.2M
Accumulated Other Comprehensive Income	(3.7M)	(5.2M)	(3.6M)	(3.1M)	(2.9M)	(2.7M)
Other Current Liab	3.4M	24.6M	6.2M	4.2M	3.1M	3.7M
Common Stock Total Equity	387.1M	393.9M	434.5M	440.3M	506.3M	531.6M
Common Stock	393.9M	434.5M	440.3M	451.3M	484.7M	509.0M
Short Long Term Debt Total	3.3M	2.8M	3.9M	3.0M	2.5M	3.0M
Current Deferred Revenue	193K	18.1M	9.4M	10.8M	7.4M	7.8M
Short Term Debt	1.5M	831K	952K	2.9M	2.3M	1.4M
Intangible Assets	47.0M	46.8M	46.7M	46.6M	46.5M	34.9M
Net Tangible Assets	54.0M	38.5M	34.7M	16.0M	18.4M	17.5M
Noncontrolling Interest In Consolidated Entity	(1.7M)	(1.1M)	(1.3M)	(1.4M)	(1.3M)	(1.2M)
Retained Earnings Total Equity	(273.4M)	(294.1M)	(337.1M)	(363.4M)	(327.0M)	(343.4M)
Non Current Liabilities Other	4.2M	3.0M	2.0M	2.9M	3.4M	3.6M
Property Plant Equipment	8.2M	5.6M	4.9M	5.7M	6.5M	6.0M
Net Receivables	4K	50.8M	297K	745K	638K	606.1K
Other Liab	3.8M	2.5M	34.6M	29.8M	34.3M	36.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Lineage Stock Analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.

Trending Assets

NLTX

Neoleukin Therapeutics

0.00 0.00 0.00

BOLT

Bolt Biotherapeutics

0.43 -0.01 -2.27

ICCC

ImmuCell

5.01 0.11 2.24

NUVB

Nuvation Bio

1.82 -0.05 -2.67

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC